Navigation Links
Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
Date:5/3/2012

nclude Claritin® (allergy), Zantac® (ulcers and reflux), OxyContin® (pain), Lopressor® (high blood pressure), Imitrex® (migraine headache), Reglan® (nausea) and Abilify® (schizophrenia, bipolar disease and depression) as well as all other antihistamines, opioids, alpha and beta blockers, serotonergics and dopaminergics. 

The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs. Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs). There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs." Without a known ligand, drug development for a given receptor is extremely difficult.

Omeros uses its proprietary high-throughput CRA to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development. Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology. Unlocking these receptors could lead to the development of drugs that act at these new targets. There is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patie
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced an update on corporate and ... structure, commitment for future funding, ongoing clinical ... In corporate news, Chief Executive Officer ...
(Date:9/2/2014)... , Sept. 2, 2014  MEI Pharma, Inc. ... focused on the clinical development of novel therapies ... enrollment in a randomized Phase II clinical trial ... combination with azacitidine in patients with previously untreated ... placebo-controlled, double-blind study enrolled a total of 108 ...
(Date:9/2/2014)... Sept. 2, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... three drugs in its lipid franchise were highlighted in ... (ESC) Congress in Barcelona Spain . ... designed to provide effective and safe therapeutic options to ... of one commercialized drug and several other drugs in ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 2Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 3Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 5
... CHICAGO, May 25, 2012  Dallas entrepreneur Clayton Redmon has ... Black Enterprise . (Photo: http://photos.prnewswire.com/prnh/20120525/DA13928 ) ... StreamVenue Healthcare , was among three ... Business Awards, People,s Choice Award presented at the ...
... PARSIPPANY, N.J., May 25, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... company, announced today that Siggi Olafsson, Watson,s President of ... the Company,s business at the Jefferies 2012 Global Healthcare ... Time at the Grand Hyatt in New York, New ...
Cached Medicine Technology:StreamVenue Healthcare CEO Named People's Choice Winner 2Watson to Present at the Jefferies 2012 Global Healthcare Conference 2
(Date:9/2/2014)... News) -- The quality of Americans, diets has improved ... the rich and poor is growing, a new study ... to date that the extensive efforts by many groups ... some payoff, but it also indicates that these efforts ... doctoral student in the department of nutrition at the ...
(Date:9/2/2014)... Amy Norton HealthDay Reporter , ... want to lose weight and boost their heart health, cutting ... a new study suggests. In a small clinical trial ... a low-carbohydrate diet lost more weight over a year than ... bigger improvements in their cholesterol and triglyceride levels, the research ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... Magee Rehabilitation Hospital returns on September 19 at The ... Hill, Pennsylvania. Over the past 25 years, the Classic, ... more than $12 million for programs and services designed ... at Magee Rehabilitation Hospital. , “The Segal Classic ...
(Date:9/2/2014)... 02, 2014 North America Resectoscopes ... Market Outlook to 2020? provides key market data ... provides value, in millions of US dollars, volume ... within market segments –,     Rigid ... Reusable) Electrodes and Bipolar (Disposable and Reusable) Electrodes). ...
(Date:9/2/2014)... 02, 2014 Humility of Mary Health Partners ... at St. Elizabeth Health Center, 1044 Belmont Ave. , The ... more than 200 common health problems as well as tips ... injury, and advice on when to seek medical attention. ... in the Youngstown Room; the evening session runs from 5:30 ...
Breaking Medicine News(10 mins):Health News:Quality of U.S. Diet Improves, Slightly 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:HMHP Offers ‘Health at Home’ Workshop 2
... of the Johns Hopkins Children,s Center and Scott Sicherer of ... caution when ordering allergy tests and to avoid making a ... article, published in the January issue of Pediatrics , ... tool in recent years, and skin-prick testing, an older weapon ...
... Doheny HealthDay Reporter , FRIDAY, Dec. 23 (HealthDay ... imaging tests between diagnosis and surgery than they did in ... -- breast ultrasounds, MRIs and mammograms -- help doctors determine ... hassles and expense of care, the study says. ...
... News) -- Reindeer have lots to do this time of ... sleighs -- but despite all their frenzied activity they manage ... overheated, researchers have found. Now, Norwegian scientists have gained ... of reindeer as they exercised on solid ground. In ...
... 23 (HealthDay News) -- Obese people who have had surgery to ... of the disease or die from cancer within five years as ... the study, published in the Dec. 1 issue of the ... Rochester, Minn., suggested their findings could change the way some doctors ...
... FRIDAY, Dec. 23 (HealthDay News) -- The holiday season can ... take steps to ensure they stay healthy through this often ... is a cancer survivor and their ranks are growing. Many ... disease and its treatment, experts at the Fred Hutchinson ...
... , FRIDAY, Dec. 23 (HealthDay News) -- Parents of ... lifestyle changes that will benefits their kids, health, a ... efforts to combat the childhood obesity epidemic among Hispanic ... United States, said the researchers at University of Texas ...
Cached Medicine News:Health News:Memo to pediatricians: Allergy tests are no magic bullets for diagnosis 2Health News:Memo to pediatricians: Allergy tests are no magic bullets for diagnosis 3Health News:Breast Cancer Patients Face More Imaging Tests Today 2Health News:Breast Cancer Patients Face More Imaging Tests Today 3Health News:Study Shows How Busy Reindeer Keep Their Cool 2Health News:Obesity Linked to Higher Esophageal Cancer Death Rates 2Health News:Cancer Survivors Should Take Steps to Keep Healthy During Holidays 2Health News:Parents May Hold Key to Healthy Weight in Hispanic Kids 2
... diagnostic capabilities combined with ease of use ... in its class. Ideal for office or ... system for Uroflowmetry, cystometry, leak point pressure, ... are available which make the OM-5 flexible ...
The Duet EnCompass Pelvic Floor Diagnostic System is the only equipment specifically designed to perform urodynamics, anorectal manometry, EMG and pudendal nerve latency studies on a single software ...
... The Corkscrew FT II (fully threaded) is ... designed to be inserted flush with the ... and anchor stability. The full thread design ... anchors with protruding eyelets. Especially advantageous when ...
... Corkscrew Parachute Tissue Anchor allows one step fixation ... ideal for arthroscopic knotless rotator cuff repair in ... has an outside thread diameter of 5 mm ... #2 FiberWire suspension sutures securely hold a thin, ...
Medicine Products: